Pharmaceutical Technology

FEBRUARY 5, 2023

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Trodelvy (sacituzumab govitecan-hziy) to treat unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer adult patients.

FDA 105

FDA Adverse Reactions Chemotherapy Labelling 105

European Pharmaceutical Review

DECEMBER 19, 2022

The US Food and Drug Administration (FDA) has approved Adstiladrin (nadofaragene firadenovec-vncg) as the first gene therapy for non-muscle-invasive bladder cancer (NMIBC) in adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive with carcinoma in situ (CIS) with or without papillary tumours.

FDA 110

FDA Adverse Reactions Immunization Vaccines 110

Pharmaceutical Technology

MAY 23, 2023

The US Food and Drug Administration (FDA) has granted approval for Blueprint Medicines’ Ayvakit (avapritinib) as the first and only treatment for indolent systemic mastocytosis (ISM) in adult patients. Dizziness, flushing, eye oedema and peripheral oedema are the most common adverse reactions for Ayvakit.

FDA 98

FDA Adverse Reactions Labelling 98

Pharmaceutical Technology

MARCH 23, 2023

The US Food and Drug Administration (FDA) has approved Incyte ’s Zynyz (retifanlimab-dlwr) to treat metastatic or recurrent locally advanced merkel cell carcinoma (MCC) in adult patients. Diarrhoea, rash, pyrexia, nausea, musculoskeletal pain, fatigue and pruritus are the most common adverse reactions observed in patients treated with Zynyz.

FDA 98

FDA Adverse Reactions Compounding Chemotherapy 98

Pharmaceutical Technology

MARCH 1, 2023

The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi ’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients. The post US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica appeared first on Pharmaceutical Technology.

FDA 98

FDA Adverse Reactions 98

Pharmaceutical Technology

FEBRUARY 20, 2023

The US Food and Drug Administration (FDA) has granted approval for Apellis Pharmaceuticals’ Syfovre (pegcetacoplan injection) to treat geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The post US FDA approves Apellis’ geographic atrophy therapy Syfovre appeared first on Pharmaceutical Technology.

FDA 98

FDA Adverse Reactions Immunization 98

Pharmaceutical Technology

SEPTEMBER 19, 2022

The US Food and Drug Administration (FDA) has awarded Accelerated Approval for bluebird bio ’s Skysona (elivaldogene autotemcel; eli-cel) for slowing neurologic dysfunction progression in early, active cerebral adrenoleukodystrophy (CALD) patients. The treatment is indicated for usage in boys aged four to 17 years with CALD. thalassemia.

FDA 98

FDA Adverse Reactions Labelling 98

European Pharmaceutical Review

DECEMBER 23, 2022

The US Food and Drug Administration (FDA) has approved Gilead’s Sunlenca (lenacapavir), a capsid inhibitor for adults living with human immunodeficiency virus type 1 (HIV-1), who cannot be successfully treated with other available treatments. After 52 weeks, 83 percent of participants continued to have HIV RNA suppression.

FDA 98

FDA Adverse Reactions Labelling 98

European Pharmaceutical Review

FEBRUARY 21, 2023

SYFOVRE (pegcetacoplan injection) is the first and only treatment approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA), a leading cause of blindness. The post FDA approves first treatment for geographic atrophy appeared first on European Pharmaceutical Review.

FDA 98

FDA Adverse Reactions 98

European Pharmaceutical Review

AUGUST 18, 2022

The US Food and Drug Administration (FDA) has approved bluebird bio’s Zynteglo (betibeglogene autotemcel; beti-cel), the first cell-based gene therapy for the treatment of adult and paediatric patients with beta-thalassemia who require regular red blood cell transfusions. .

FDA 98

FDA Adverse Reactions 98

pharmaphorum

AUGUST 6, 2020

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Ocular adverse reactions occurred in 77% of the 218 patients in the pooled safety population and included keratopathy (76%), changes in visual acuity (55%), blurred vision (27%) and dry eye (19%).

FDA 87

FDA Adverse Reactions Packaging 87

pharmaphorum

OCTOBER 26, 2020

US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot. There are many possible factors that could have caused the event.”.

Vaccines 95

Vaccines Adverse Reactions FDA 95

pharmaphorum

JANUARY 18, 2021

“Out of an extreme abundance of caution and also recognising the extremely limited supply of vaccine, we are recommending that providers use other available vaccine inventory and pause the administration of vaccines from Moderna lot 041L20A until the investigation by the CDC, FDA, Moderna and the state is complete.

Vaccines 136

Vaccines Adverse Reactions FDA 136

Digital Pharmacist

OCTOBER 24, 2022

The FDA protects public health by ensuring the efficacy and safety of human and veterinary drugs, including biological products and medical devices. It is critical for the FDA to continue to develop new advances in therapies to aid our communities in order to achieve better lives through better health. Date of Approval: 9/30/2022.

FDA 75

FDA Adverse Reactions Pharmaceutical Companies Pharmaceutical Companies 75

PharmExec

JUNE 2, 2023

New program seeks to reduce misuse and adverse reactions by simplifying prescription labels.

Adverse Reactions 52

Adverse Reactions Labelling FDA 52

European Pharmaceutical Review

JUNE 29, 2023

The US Food and Drug Administration (FDA) has approved Lantidra, the first cell therapy for certain adults with Type 1 diabetes. Lantidra’s mechanism of action The primary mechanism of action of Lantidra is believed to be the secretion of insulin by the infused allogeneic islet beta cells, FDA stated.

Adverse Reactions 98

Adverse Reactions FDA 98

pharmaphorum

OCTOBER 19, 2020

Combination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies. The post FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies appeared first on. months compared with 4.1

Adverse Reactions 59

Adverse Reactions FDA Chemotherapy Labelling 59

Pharmaceutical Technology

FEBRUARY 3, 2023

The US Food and Drug Administration (FDA) has granted approval to Amgen and AstraZeneca ’s Tezspire (tezepelumab-ekko) for self-administration using a single-use, pre-filled pen for severe asthma patients aged 12 years and above. Pharyngitis, arthralgia, and back pain are the most common adverse reactions of the antibody.

FDA 59

FDA Adverse Reactions 59

The FDA Law Blog

SEPTEMBER 23, 2022

By Ellis Unger, Principal Drug Regulatory Expert — On September 14, 2022, FDA/CDER/Office of New Drugs, in collaboration with the Duke-Margolis Center for Health Policy, hosted a virtual meeting on advancing premarket safety analytics , including sessions on new FDA Medical Queries and standardized presentations of safety data.

Labelling 52

Labelling Adverse Reactions FDA 52

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab ‘s Epkinly (epcoritamab-bysp) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients. The FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients. “As

FDA 52

FDA Adverse Reactions Chemotherapy Patient Care 52

Pharmaceutical Technology

NOVEMBER 9, 2022

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC).

Chemotherapy 52

Chemotherapy FDA Adverse Reactions 52

The FDA Law Blog

MARCH 7, 2024

In 2006, FDA stated that DMCs were not recommended “for most clinical studies,” particularly those in early product development, short-term studies, or studies addressing less severe outcomes. Increased Connections Between a DMC and FDA? However, in contrast to DMCs, such an entity should remain blinded to efficacy data.

Documentation 105

Documentation FDA Adverse Reactions Communication 105

Pharmaceutical Technology

JUNE 6, 2023

American Regent and Daiichi Sankyo have announced that the INJECTAFER (ferric carboxymaltose injection) has received approval from the US Food and Drug Administration (FDA) to treat iron deficiency in adult patients with heart failure. Approximately 2.8

FDA 52

FDA Adverse Reactions 52

pharmaphorum

APRIL 1, 2021

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. In the trial, 8% of patients dropped out because of adverse events and 2.8% quit because of an infection.

Adverse Reactions 59

Adverse Reactions Labelling Chemotherapy FDA 59

Pharmaceutical Technology

MARCH 17, 2023

The US Food and Drug Administration (FDA) has granted approval for Novartis ’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib), to treat BRAF V600E low-grade glioma (LGG) in paediatric patients as young as one year.

Adverse Reactions 52

Adverse Reactions FDA Chemotherapy 52

Pharmaceutical Technology

AUGUST 25, 2022

The US Food and Drug Administration (FDA) has gra nted approval for AbbVie and Janssen Biotech’s Imbruvica (ibrutinib) to treat chronic graft versus host disease (cGVHD) in paediatric patients aged one year and above. The post US FDA approves AbbVie-Janssen’s Imbruvica for cGVHD in children appeared first on Pharmaceutical Technology.

FDA 52

FDA Adverse Reactions Dosage Labelling 52

STAT

SEPTEMBER 7, 2022

 Moving forward, the company will expand patient monitoring in the trial to watch for low magnesium levels, which had resulted in a serious adverse reaction in one study participant that led the FDA to suspend testing earlier this year.

Adverse Reactions 52

Adverse Reactions FDA Vaccines 52

pharmaphorum

JANUARY 23, 2023

Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). The post BeiGene’s Brukinsa FDA approved for CLL/SLL appeared first on.

FDA 52

FDA Adverse Reactions Dosage 52

European Pharmaceutical Review

SEPTEMBER 2, 2022

This can be achieved by reducing the burden of adverse reactions or by optimising benefits through patient selection (eg, contraindications, recommendations of use, warnings, concomitant medicine[s], or certain test parameters) and treatment management (eg, specific dosing regimen, relevant testing, patient follow-up).

Adverse Reactions 96

Adverse Reactions Documentation Medical Schools Packaging 96

pharmaphorum

APRIL 14, 2021

Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. . Accelerated approval is based on early data and the FDA will require long-term survival data for the drug to remain on the market permanently in this indication. Median duration of response was 7.2

Adverse Reactions 52

Adverse Reactions Chemotherapy FDA 52

pharmaphorum

JUNE 3, 2021

The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly genericised market. The post After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi appeared first on.

FDA 52

FDA Adverse Reactions Generic Medicine Labelling 52

pharmaphorum

JUNE 16, 2021

Reported adverse reactions tended to be mild, including somnolence, dizziness sedation, but the rate of somnolence in particular (15% versus 3% for placebo) still led to questions about the potential uptake of the drug if approved.

Adverse Reactions 94

Adverse Reactions FDA 94

The Checkup by Singlecare

JANUARY 23, 2024

Allergic reactions Hypoglycemia (low blood sugar levels) Elevated liver enzymes Kidney function decline Bleeding Overdose toxicity How soon do black seed oil side effects start? The onset time of adverse reactions to black cumin seed oil has not been elucidated to date.

Adverse Reactions 102

Adverse Reactions Communication FDA 102

pharmaphorum

JANUARY 22, 2021

The FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the virus at bay with a monthly injection instead of daily pill regimen. The clinical data supplied by ViiV was enough to support approval, however, and the FDA has finally given the go-ahead for Cabenuva.

Adverse Reactions 71

Adverse Reactions FDA 71

The Checkup by Singlecare

MARCH 19, 2024

Beware of adverse reactions and drug-drug interactions when taking any of these. Food and Drug Administration (FDA). A common mistake is taking Tylenol and a combination cold medicine together, and if the cold medicine contains acetaminophen too, an overdose of acetaminophen can result.

Adverse Reactions 78

Adverse Reactions Packaging Dosage FDA 78

The Checkup by Singlecare

MAY 10, 2023

Food and Drug Administration (FDA) began requiring a “ black box warning ” on antidepressants. There is a dance to be done, and the right balance must be found between relief of symptoms and avoidance of adverse reactions,” Roye says. “If In 2004, the U.S.

Adverse Reactions 98

Adverse Reactions Dosage FDA 98

The Checkup by Singlecare

JULY 31, 2023

Food and Drug Administration (FDA) for use in humans—but it works similarly in dogs. Zyrtec dosage for dogs The FDA hasn’t approved Zyrtec for treating allergies in dogs, so there is no dog-specific Zyrtec product available. What is Zyrtec used for in dogs?

Dosage 98

Dosage Adverse Reactions FDA Immunization 98